reports
Relief Therapeutics Holding S.A.: 1 director
A director at Relief Therapeutics Holding S.A. sold 6,000 shares at 4.072CHF and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Con...
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 18.09.2024 / 07:00 CET/CEST Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 GENEVA (SEPT. 18, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has completed dosing in its ...
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at...
Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 02.09.2024 / 07:00 CET/CEST Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 GENEVA (SEPT. 2, 2024) – (SIX: , OTCQB: , ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced today that interim data from its clinical trial evaluating PKU GOLIKE® will be presented at the (SSIEM) 2024 Annual Symposium ...
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary Gene...
Relief Therapeutics Holding SA / Key word(s): AGMEGM RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting 26.04.2024 / 17:30 CET/CEST RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority GENEVA (APR. 26, 2024) – (SIX: , OTCQB: , ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announces the results of the extraordinary general ...
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual ...
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 01.09.2023 / 07:45 CET/CEST Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference GENEVA (SEPT. 1, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that Jack Weinstein, chief executive officer, will present a company overview during...
Relief Therapeutics Announces Extension of Distribution Agreement for ...
Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health 19.07.2023 / 07:30 CET/CEST Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE® GENEVA (July 19, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovati...
Relief Therapeutics Announces Swissmedic Approval and Operation of New...
Relief Therapeutics Holding SA / Key word(s): Regulatory Approval Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory 15.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Swissmedic Approval and Operation of New Good Manufacturing Practice-Compliant Laboratory The state-of-the-art quality control and research and development laboratory in Balerna, Switzerland is run by APR Applied Pharma Research SA, a Relief Therapeutics subsidiary GENEVA (May 15, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics, or...
Relief Therapeutics Announces Implementation Timeline for Reverse Spli...
Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares 03.05.2023 / 07:00 CET/CEST Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares GENEVA (May 3, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for ...
Relief Therapeutics Announces Results of Extraordinary General Meeting...
Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders 28.04.2023 / 19:00 CET/CEST Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated upon Nasdaq listing GENEVA (April 28, 2023) – (SIX: , OTCQB: , ) (Relief Therapeutics, or the Company), a biopharmaceutical ...
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in E...
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe 16.03.2023 / 07:00 CET/CEST Relief Therapeutics Announces Availability of New PKU GOLIKE BARs® in Europe The Company also discloses it has transferred most of the funds it held with Credit Suisse and has no funds with recently closed U.S. banks GENEVA, MAR. 16, 2023 – (SIX: , OTCQB: , ) ("Relief Therapeutics" or the "Company"), a biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy...
Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Ava...
Relief Therapeutics Holding SA / Key word(s): Market Launch Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE Bars 28.02.2023 / 07:00 CET/CEST Relief Therapeutics Recognizes Rare Disease Day and Announces U.S. Availability of New PKU GOLIKE® Bars Paolo Galfetti, chief operating officer of Relief Therapeutics and chief executive officer of APR Applied Pharma Research SA, shares his family’s rare story of living with phenylketonuria GENEVA, FEB. 28, 2023 – (SIX: , OTCQB: , ) ("Relief Therapeutics" or the "Company"), a biophar...
Relief Therapeutics to Participate in January Investor Meetings
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in January Investor Meetings 14.12.2022 / 07:00 CET/CEST Relief Therapeutics to Participate in January Investor Meetings GENEVA, DEC. 14, 2022 – (SIX: , OTCQB: , ) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis, today announced the Company will present at the 15th Annual Biotech ShowcaseTM and host institutional inv...
APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a...
Relief Therapeutics Holding SA / Key word(s): Miscellaneous APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival 21.11.2022 / 07:00 CET/CEST APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival Geneva, Switzerland, November 21, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent ...
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europ...
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum 12.09.2022 / 07:05 CET/CEST Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe ForumGeneva, Switzerland, September 12, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Fina...
Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual ...
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference 07.09.2022 / 07:00 CET/CEST Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Geneva, Switzerland, September 7, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, toda...
Relief Therapeutics to Participate in Industry and Investor Conference...
Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in Industry and Investor Conferences in May 09.05.2022 / 07:00 Relief Therapeutics to Participate in Industry and Investor Conferences in May Geneva, Switzerland, May 9, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following industry and investor conferences in May. - May 16-18 (in-person)/Ma...
EQS-News: Relief Therapeutics Expands Its Board of Directors with the ...
EQS-News: RELIEF THERAPEUTICS Holding AG / Key word(s): Personnel Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock 02.02.2022 / 07:00 Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock Industry Executive Brings Nearly 30 Years of Biopharmaceutical Sales and Commercial ExpertiseGeneva, Switzerland, February 2, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high u...
EQS-News: Relief Therapeutics to Participate in Virtual Investor Confe...
EQS-News: RELIEF THERAPEUTICS Holding AG / Key word(s): Conference Relief Therapeutics to Participate in Virtual Investor Conferences in January 05.01.2022 / 07:00 Relief Therapeutics to Participate in Virtual Investor Conferences in JanuaryGeneva, Switzerland, January 5, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced participation in the following virtual investor conferences in January. - January 10-13: ...
EQS-News: Relief Therapeutics to Participate in the H.C. Wainwright 23...
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Conference Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference 08.09.2021 / 07:00 Relief Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference Geneva, Switzerland, September 8, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that Jack Weinstein, Relief's Chief Financia...
EQS-News: Relief Reports that U.S. Collaboration Partner has Announced...
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study Relief Reports that U.S. Collaboration Partner has Announced a New Finding from Aviptadil Phase 2b/3 Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 31.08.2021 / 07:00 Relief Reports that its U.S. Collaboration Partner has Announced a New Finding from the ZYESAMI(TM) (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19 Geneva, Switzerland, August 31, 2021 - RELIEF THERAPEUTICS Holdi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.